ACOG
Alpha Cognition Inc

332
Loading...
Loading...
News
all
press releases
Alpha Cognition Inc. (ACOG) Reports Q2 Loss, Tops Revenue Estimates
Alpha Cognition Inc. (ACOG) delivered earnings and revenue surprises of -41.30% and +0.18%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
More News
News Placeholder
What Makes Alpha Cognition Inc. (ACOG) a New Strong Buy Stock
Alpha Cognition Inc. (ACOG) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·3mo ago
News Placeholder
Is Alpha Cognition Inc. (ACOG) Outperforming Other Medical Stocks This Year?
Here is how Alpha Cognition Inc. (ACOG) and Astellas Pharma Inc. (ALPMY) have performed compared to their sector so far this year.
Zacks·3mo ago
News Placeholder
Should You Buy Alpha Cognition Inc. (ACOG) After Golden Cross?
Zacks·3mo ago
News Placeholder
Alpha Cognition Inc. (ACOG) Reports Q1 Loss, Misses Revenue Estimates
Zacks·4mo ago
News Placeholder
Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL
Alpha Cognition Inc. (Nasdaq: ACOG) (Alpha Cognition, or the Company), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today...
Business Wire·8mo ago
News Placeholder
Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimers Disease, in China
Alpha Cognition, Inc. (Nasdaq: ACOG) (ACI or the Company), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, and China Medical System Holdings...
Business Wire·9mo ago
News Placeholder
Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimers Long-Term Care Market During Investor Update Call
Alpha Cognition Inc. (Nasdaq: ACOG) (Alpha Cognition, or the Company), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today...
Business Wire·9mo ago
News Placeholder
Alpha Cognition Announces Partial Exercise of Over-allotment Option
Alpha Cognition Inc. (Nasdaq: ACOG) (Alpha Cognition, or the Company), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today...
Business Wire·9mo ago
News Placeholder
Alpha Cognition Announces Voluntary Delisting from CSE
Alpha Cognition Inc. (NASDAQ: ACOG) (Alpha Cognition, or the Company), announces that in connection with the Companys listing on the Nasdaq Capital Market the Company will voluntarily delist its...
Business Wire·10mo ago

Latest ACOG News

View

Advertisement. Remove ads.

Advertisement. Remove ads.